Group items tagged

The Royal Pharmaceutical Society (RPS) has appointed Neville Carter as its new chief education and membership officer. Neville joins RPS from the Royal Society of Medicine (RSM) where he is currently director of engagement, leading a team of over 60 and responsible for creating a combined directorate accountable for education, membership, philanthropy, and business development. He has, in particular, led on the development of a digital education strategy and launched professional development training programmes for members. Prior to joining the RSM, Neville worked as director of product and sales at the British Medical Association with responsibility for membership growth, supporting corporate transformation and developing and managing member benefits and relationships with third-party providers to support revenue growth. He also has senior manager experience at the RAC and at British Airways. Commenting on the appointment, Paul Bennett, RPS CEO, said: "I'm delighted that Neville will be joining our Executive team. He brings a wealth of relevant experience and this, in combination with a strong existing education and membership team at RPS and a clear ambition to strengthen the relevant functions further, will enable the organisation to deliver a dynamic offering for our members.

Pharmaceutical giant GlaxoSmithKline aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults. RSV is a leading cause of pneumonia in toddlers and the elderly, but the complex molecular structure of the virus and safety concerns have stymied efforts to develop a vaccine since the virus was first discovered in 1956. Companies including Pfizer, J&J, Sanofi, Moderna and AstraZeneca are also racing to get an RSV therapy or vaccine approved. The latest GSK trial is the first to show statistically significant efficacy for RSV in adults aged 60 years and older, the British drugmaker said of the ongoing study on Friday (June 10). If approved, the RSV vaccine is expected to generate billions for GSK, which is already the world's biggest vaccine maker by sales but has faced pressure from activist investors such as Elliott Management who have urged the London-based company to shore up its drug pipeline.

Boots witnessed a 'record-breaking' performance for beauty driving retail sales with a growth of 16 per cent in the three months to 28 February 2023. The beauty category delivered a record January, and premium beauty saw its biggest ever sales week in December. Skincare reported three consecutive weeks of record sales in December driven by the 'expert skincare' category in which brands including No7, La Roche-Posay, CeraVe and Eucerin proved popular. Boots beauty transformation strategy continued with 19 new beauty halls opened in Q2 and the 170th store to receive a beauty makeover opening at Westfield White City post-period end. Boots now stocks over 500 big name and cult beauty brands and exclusively sells the UK's leading skincare brand, No7. The business reported its eighth consecutive quarter of market share growth with gains across all categories, led by beauty - the stand-out performer of the quarter. Footfall, basket size and the number of Advantage Card customers all increased, as more people chose to shop at Boots. The Christmas period was particularly strong with retail sales in the five weeks to 31 December up 17.4% and outperforming the market. Boots further expanded its value offering in the quarter, announcing its biggest ever savings as part of its continued focus on the affordability of life's essentials. This included the addition of 60 new products to the Boots Everyday label as well as the extension of its Price Advantage scheme, which has to date resulted in £30 million of customer savings and now includes discounts on over 800 products every month.

The UK based Pharma giant Futura Medical Plc's lead product, Eroxon, a topical Stim-gel is now available on NHS prescription in England and Wales for the treatment of Erectile Dysfunction (ED). The Muti-Drug Resistant (MDR) approved alternative to PDE5i, Eroxon is available as an over-the counter off shelf at retailers like Boots and Superdrug; and is available on NHS prescription in England and Wales as a CE-marked medical device. Erectile dysfunction (ED), also known as impotence, is the inability to get and maintain an erection, typically concerning men over the age of 40 due to both, psychological and physical causes such as anxiety, depression, diabetes, and obesity. According to UK Conformity Assessed (UKCA), the approval of the medication is based on evidence from 2 Phase three clinical studies, which showed that 60 per cent of patients taking Eroxon achieved Minimal Clinically Important Differences (MCID) at 12 weeks.

Join the battle against pain! Worldwide, 93% experience it annually, with 1 in 3 enduring daily agony. But our approach needs refinement. Introducing our Pain Management Webinar! In just 60 minutes, equip yourself with strategies to combat pain effectively. Here's what's covered: Pharmacists' Evolving Role: Moving beyond medication. Perfecting Pain Assessment: Quantifying patient discomfort. #ListenToPain: Enhancing patient communication. Tailored for British pharmacists addressing acute and chronic pain. Seize this opportunity to make a tangible difference. Reserve your spot now for invaluable insights!

Join the fight against pain! Globally, 93% of people experience it annually, with 1 in 3 enduring daily suffering. However, our approach requires improvement. Introducing our Pain Management Webinar! In just 60 minutes, equip yourself with strategies to effectively combat pain. Here's what we'll cover: Pharmacists' Evolving Role: Moving beyond mere medication. Refining Pain Assessment: Quantifying patient discomfort accurately. #ListenToPain: Improving patient communication. Tailored for British pharmacists dealing with both acute and chronic pain. Seize this opportunity to make a real difference. Reserve your spot now for invaluable insights!

The Royal Pharmaceutical Society (RPS) has released findings from its fifth annual workforce wellbeing survey, which was conducted in collaboration with the profession's charity, Pharmacist Support. Exposing the mental health challenges faced by pharmacists, the survey revealed a troubling statistic: 86 per cent of pharmacists are at a high risk of burnout. Inadequate staffing was the main factor contributing to burnout, followed by lack of work-life balance, insufficient protected learning time, absence of colleague or senior support, and long working hours. While pharmacies are encouraged to provide more clinical services, more than 60 per cent of pharmacists surveyed reported that they were not being offered "sufficient protected learning time" to focus on their professional development and learning needs. The survey also exposed a distressing trend of workplace abuse, with over 40 per cent of pharmacists reporting verbal abuse from the public, and 25 per cent from colleagues or managers.

Superdrug is bolstering its physical presence by launching 25 new stores this year as it celebrates its 60th year on the British high street. Additionally, the health and beauty retailer has announced plans to extend seven of its existing branches and refit another 60 throughout 2024. However, the retailer has confirmed the locations for only four upcoming stores - Wheatley Centre Shopping Parkin Doncaster, St David's Centre in Cardiff, Bluewater Shopping Centre and Westfield Stratford City. As reported by Mirror, the Donacaster site is expected to open by the end of this month, followed by the relocation of its existing Cardiff store to a new 11,3000 sq. ft space shortly thereafter. Superdrug is also shifting its Westfield Stratford City store, doubling its size to 9,892 sq. ft. Likely to be opened in the summer, it will be one of the retailer's biggest stores.

More than half of people (52%) do not feel confident in treating backache and less than half (44%) uses community pharmacists' advice as their first step on self-treatable conditions, a self-care attitudes 2022 survey has revealed. PAGB, the consumer healthcare association, surveyed over 2,000 adults across the UK about their attitudes towards self-care and access to health services. According to the survey, the public is in favour of self-care but many people lack the confidence and knowledge to care for the most common self-treatable conditions including backaches, headaches, diarrhoea and constipation. Four in five respondents (79%) said that people should take more responsibility for their own health and three-quarters (73%) believe that the NHS should make self-treatment easier. Behaviours around the current use of pharmacy varied - with less than half (44%) using community pharmacists as their first step in in getting advice on self-treatable conditions - but longer term attitudes were encouraging, with 69% supporting the idea of GPs being able to make referrals to pharmacists. Respondents also supported expanding the role of pharmacists so that their skills can be better utilised.

If you are looking for hair fall solution oil then your search ends here because our best ayurvedic hair growth oil is made naturally to give you healthy hair. Moreover, it helps in preventing hair loss and forms an essential part of your hair care routine. This is the best ayurvedic hair regrowth oil for men and Women to provide your hair with the necessary nourishment they need without causing any side effects. For More Details, please visit: https://www.tribalblackoil.com contact on +91 9229337811 Email id: info@tribalblackoil.com